ADA 2025 20 - 23 June 2025

Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW

Authors :

Peter Rossing^1,2; Morten Lindhardt^2,3; Christian Klyver Tikkanen⁴; Jyothi Menon⁵; Juliette Cattin⁶; Barnaby Hunt⁶; Samuel JP Malkin⁶; Barrie Chubb⁵; Tina Damgaard⁴; Rikke Borg^2,7

Affiliations

View Details Hide Details

Download poster (.pdf)

Keywords

Diabetes

Chronic Kidney Disease

Congress poster

GLP-1 RA

Semaglutide

Search Science Hub

Are you a healthcare professional?

Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW